| Stage | BRBR | % of rev | MDLZ | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $570M | 100.00% | $10.0B | 100.00% | MDLZ ×17.47 |
| Gross profit | $163M | 28.63% | $3.9B | 39.37% | MDLZ +10.7pp |
| Operating income | $65M | 11.47% | $1.8B | 17.64% | MDLZ +6.2pp |
| Pre-tax income | $46M | 7.98% | $1.7B | 17.27% | MDLZ +9.3pp |
| Net income | $34M | 6.00% | $1.3B | 13.12% | MDLZ +7.1pp |
| Stage | BRBR | MDLZ | Gap · A − B |
|---|---|---|---|
| Revenue | $570M100.00% | $10.0B100.00% | MDLZ ×17.47 |
| Gross profit | 28.63%$163M | 39.37%$3.9B | MDLZ +10.7pp |
| Operating income | 11.47%$65M | 17.64%$1.8B | MDLZ +6.2pp |
| Pre-tax income | 7.98%$46M | 17.27%$1.7B | MDLZ +9.3pp |
| Net income |
| 6.00%$34M |
| 13.12%$1.3B |
| MDLZ +7.1pp |
No disclosed counterparties: MDLZ.
None